{"page":{"totalFilteredElements":68},"studies":[{"active":true,"description":"<div>A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)</div>","eudractNumber":"2024-515008-38-00","id":11262,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06627647","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-08T08:46:54+02:00","shortTitle":"D702FC00001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"DESTINY-Biliary\nTract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and\nRilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab\nfor First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract\nCancer","eudractNumber":"2023-508057-19-00","id":10413,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06467357","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-04-14T08:12:40+02:00","shortTitle":"DESTINY-BTC 01 D781PC00001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Phase 3, Randomized, Open-Label Study of Belentamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide, and Dexamethasone in Participants with Newly Diagnose Multiple Myeloma who are inelegible for ASCT<br />","eudractNumber":"2024-516030-35-00","id":10407,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-10-06T08:42:39+02:00","shortTitle":"DREAMM-10","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Lenalidomide, Adriamycin, Dexamethasone \n(RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction\n in Newly Diagnosed Multiple Myeloma Followed by Response-adapted \nConsolidation and Lenalidomide Maintance &#8211; A Randomized Multicenter \nPhase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)","eudractNumber":"2009-016616-21","id":414,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT01685814","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2012-07-20T09:58:17+02:00","shortTitle":"DSMM XIV","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<b>GMMG HD9/ DSMM XVIII:</b> A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.","eudractNumber":"2023-507402-13","id":9091,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06216158","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-04-03T08:59:37+02:00","shortTitle":"DSMM XVIII [GMMG HD9]","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued</div><div>Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients</div>","eudractNumber":"2024-519827-16-00","id":11504,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06932562","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-11-10T09:57:13+01:00","shortTitle":"EMN 39","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase III, Randomized, Open-Label, Multi-Center, Global&#160;Study of Volrustomig (MEDI5752) as Sequential Therapy Versus&#160;Observation in Participants with Unresected Locally Advanced&#160;Head and Neck Squamous Cell Carcinoma, Who Have Not&#160;Progressed Following Definitive Concurrent Chemoradiotherapy&#160;(eVOLVE-HNSCC)<div><br /></div><div><b>D798EC00001</b><br /></div>","eudractNumber":"2023-506294-36","id":9113,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[{"name":"CTLA-4 (cytotoxic T-lymphocyte-associated Protein 4)","id":"mt_42"},{"name":"HPV16","id":"mt_86"},{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06129864","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-10-21T09:15:23+02:00","shortTitle":"EVOLVE-HNSCC D798EC00001","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III \"PREVENT\" Trial of the AIO /CAOGI /ACO<div><br /></div>","eudractNumber":"2017-003832-35","id":6238,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"}],"mutations":[],"nctNumber":"NCT04447352","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-12-16T14:24:11+01:00","shortTitle":"HIPEC/FLOT9 (PREVENT)","therapeutical":true,"therapyLines":[{"id":"tl_8","name":"Advanced"}]},{"active":true,"description":"A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab&#160;Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With&#160;Previously Untreated Advanced Melanoma (PRISM-MEL-301)","eudractNumber":"2023-505306-42","id":9869,"indications":[{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"BRAF","id":"mt_9"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF V600","id":"mt_5"},{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"}],"nctNumber":"NCT06112314","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-06T09:57:42+01:00","shortTitle":"Immunocore IMC-F106C-301","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase III, Randomized, open-label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-mutated, advanced or metastatic non-squamous non&#8722;small cell lung cancer","eudractNumber":"2024-518365-10-00","id":11679,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"KRAS-G12C","id":"mt_250"}],"nctNumber":"NCT06793215","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-01T09:29:01+01:00","shortTitle":"KRAScendo 2","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"}]}]}